Merck's €190m biopharm plan

Gordon, Michael
September 2006
ICIS Chemical Business;9/4/2006, Vol. 1 Issue 33, p33
Trade Publication
The article reports on the plan of Merck to invest €190 million in a biopharmaceutical plant at its Darmstadt headquarters in Germany. The plant will manufacture the latest generation of biologically active ingredients for the treatment of cancer. It will also produce the monoclonal antibody Erbitux for the treatment of colorectal and head and neck cancer.


Related Articles

  • Medarex Sharing up to $225M in Antibody Deal.  // Bioworld Week;4/27/2009, Vol. 17 Issue 17, p3 

    The article reports on the $225 million licence deal between Merck & Co. Inc. as well as Medarex Inc. and Massachusetts Biologic Laboratories regarding the combined monoclonal antibodies developed by the latter companies. It says that the deal enables Merck to gain worldwide rights to develop...

  • Cuts Emissions 300 Tons Annually.  // Plant Engineering;Apr2001, Vol. 55 Issue 4, pA11 

    Focuses on the maintenance of the Stonewall plant of Merck & Co., Inc. in Elkton, Virginia. Facility background; Partnership of Merck with local stakeholder; Procurement of Babcock & Wilcox FM120-112-LH boilers.

  • Deal watch: Monoclonal antibodies targeting Clostridium difficile licensed to Merck.  // Nature Reviews Drug Discovery;Jun2009, Vol. 8 Issue 6, p442 

    The article analyzes the licensing agreement that Merck & Co. Inc. has signed for an investigational human monoclonal antibody (mAb) combination, co-developed by Medarex Inc. and Massachusetts Biological Laboratories (MBL) for the treatment of Clostridium difficile (C. difficile) infection. The...

  • Can 'double blockbuster' strengthen Amgen's backbone? Sheridan, Cormac // Nature Biotechnology;Apr2008, Vol. 26 Issue 4, p361 

    The article reports on the challenges faced by Amgen Inc. for its human monoclonal antibody denosumab in Thousand Oaks, California. Accordingly, the antibody will help Amgen to make up its falling revenue from its troubled Epogen (epoetin-α0) franchise, provided that the company can prove the...

  • Pembrolizumab: First PD-1 blocking agent for advanced melanoma. ALDRIDGE YOUNG, CARA // Pharmacy Today;Nov2014, Vol. 20 Issue 11, p42 

    The article reports on the U.S. Food and Drug Administration's approval of the drug pembrolizumab for the treatment of patients with advanced or unresectable melanoma. The drug is a humanized monoclonal antibody, marketed as Keytruda and manufactured by Merck & Co. Information about the drug's...

  • Medarex Sharing up to $225M from Antibody Deal with Merck. Hollingsworth, Catherine // BioWorld Today;4/22/2009, Vol. 20 Issue 76, p1 

    The article reports on the licensing of a combination of monoclonal antibodies co-developed by Medarex Inx. and Massachusetts Biologic Laboratories to drug company Merck & Co. Inc. in a deal worth $225 million (M). The deal gave Merck the worldwide righst to develop and commercialize CDA-1 and...

  • Cervical and Ovarian Cancers Update.  // PharmaWatch: Cancer;Jan2006, Vol. 5 Issue 1, p6 

    The article presents news related to female cervical and ovarian cancers. Merck & Co. Inc., New Jersey-based pharmaceutical giant has filed for the U.S. Food and Drug Administration approval of its experimental cervical cancer vaccine Gardasil. Unither Pharmaceuticals has completed enrollment of...

  • Feature Analysis: Merck & Co/Amrad: an uncertain pathway to success.  // PharmaWatch: Monthly Review;Oct2005, Vol. 4 Issue 10, p29 

    The article reports that Amrad Corp. Ltd. and Merck & Co. Inc. have selected a lead monoclonal antibody for development in severe asthma. The antibody holds promise for difficult-to-treat patients and has sales potential in excess of $1 billion. Given asthma's complex pathophysiology, it is...

  • Arrowhead Enters into Antibody Candidate Evaluation Agreement with Merck.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article informs about the agreement between Arrowhead Research Corp. and Merck & Co. Inc. It informs that this agreement is aimed at evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead's human-derived peptide targeting and discovery program. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics